866-997-4948(US-Canada Toll Free)

Breast Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Dec 2015

Category :

Cancer

No. of Pages : 2995 Pages

Breast Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Breast Cancer - Pipeline Review, H2 2015, provides an overview of the Breast Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 18
Breast Cancer Overview 19
Therapeutics Development 20
Breast Cancer - Therapeutics under Development by Companies 22
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 60
Breast Cancer - Pipeline Products Glance 68
Breast Cancer - Products under Development by Companies 72
Breast Cancer - Products under Investigation by Universities/Institutes 130
Breast Cancer - Companies Involved in Therapeutics Development 143
Breast Cancer - Therapeutics Assessment 556
Drug Profiles 620
Breast Cancer - Recent Pipeline Updates 2165
Breast Cancer - Dormant Projects 2820
Breast Cancer - Discontinued Products 2869
Breast Cancer - Product Development Milestones 2880
Appendix 2889

List of Tables
Number of Products under Development for Breast Cancer, H2 2015 125
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015 126
Number of Products under Development by Companies, H2 2015 128
Number of Products under Development by Companies, H2 2015 (Contd..1) 129
Number of Products under Development by Companies, H2 2015 (Contd..2) 130
Number of Products under Development by Companies, H2 2015 (Contd..3) 131
Number of Products under Development by Companies, H2 2015 (Contd..4) 132
Number of Products under Development by Companies, H2 2015 (Contd..5) 133
Number of Products under Development by Companies, H2 2015 (Contd..6) 134
Number of Products under Development by Companies, H2 2015 (Contd..7) 135
Number of Products under Development by Companies, H2 2015 (Contd..8) 136
Number of Products under Development by Companies, H2 2015 (Contd..9) 137
Number of Products under Development by Companies, H2 2015 (Contd..10) 138
Number of Products under Development by Companies, H2 2015 (Contd..11) 139
Number of Products under Development by Companies, H2 2015 (Contd..12) 140
Number of Products under Development by Companies, H2 2015 (Contd..13) 141
Number of Products under Development by Companies, H2 2015 (Contd..14) 142
Number of Products under Development by Companies, H2 2015 (Contd..15) 143
Number of Products under Development by Companies, H2 2015 (Contd..16) 144
Number of Products under Development by Companies, H2 2015 (Contd..17) 145
Number of Products under Development by Companies, H2 2015 (Contd..18) 146
Number of Products under Development by Companies, H2 2015 (Contd..19) 147
Number of Products under Development by Companies, H2 2015 (Contd..20) 148
Number of Products under Development by Companies, H2 2015 (Contd..21) 149
Number of Products under Development by Companies, H2 2015 (Contd..22) 150
Number of Products under Development by Companies, H2 2015 (Contd..23) 151
Number of Products under Development by Companies, H2 2015 (Contd..24) 152
Number of Products under Development by Companies, H2 2015 (Contd..25) 153
Number of Products under Development by Companies, H2 2015 (Contd..26) 154
Number of Products under Development by Companies, H2 2015 (Contd..27) 155
Number of Products under Development by Companies, H2 2015 (Contd..28) 156
Number of Products under Development by Companies, H2 2015 (Contd..29) 157
Number of Products under Development by Companies, H2 2015 (Contd..30) 158
Number of Products under Development by Companies, H2 2015 (Contd..31) 159
Number of Products under Development by Companies, H2 2015 (Contd..32) 160
Number of Products under Development by Companies, H2 2015 (Contd..33) 161
Number of Products under Development by Companies, H2 2015 (Contd..34) 162
Number of Products under Development by Companies, H2 2015 (Contd..35) 163
Number of Products under Development by Companies, H2 2015 (Contd..36) 164
Number of Products under Investigation by Universities/Institutes, H2 2015 165
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 166
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 167
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 168
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 169
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5) 170
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..6) 171
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..7) 172
Comparative Analysis by Late Stage Development, H2 2015 173
Comparative Analysis by Clinical Stage Development, H2 2015 174
Comparative Analysis by Early Stage Development, H2 2015 175
Comparative Analysis by Unknown Stage Development, H2 2015 176
Products under Development by Companies, H2 2015 177
Products under Development by Companies, H2 2015 (Contd..1) 178
Products under Development by Companies, H2 2015 (Contd..2) 179
Products under Development by Companies, H2 2015 (Contd..3) 180
Products under Development by Companies, H2 2015 (Contd..4) 181
Products under Development by Companies, H2 2015 (Contd..5) 182
Products under Development by Companies, H2 2015 (Contd..6) 183
Products under Development by Companies, H2 2015 (Contd..7) 184
Products under Development by Companies, H2 2015 (Contd..8) 185
Products under Development by Companies, H2 2015 (Contd..9) 186
Products under Development by Companies, H2 2015 (Contd..10) 187
Products under Development by Companies, H2 2015 (Contd..11) 188
Products under Development by Companies, H2 2015 (Contd..12) 189
Products under Development by Companies, H2 2015 (Contd..13) 190
Products under Development by Companies, H2 2015 (Contd..14) 191
Products under Development by Companies, H2 2015 (Contd..15) 192
Products under Development by Companies, H2 2015 (Contd..16) 193
Products under Development by Companies, H2 2015 (Contd..17) 194
Products under Development by Companies, H2 2015 (Contd..18) 195
Products under Development by Companies, H2 2015 (Contd..19) 196
Products under Development by Companies, H2 2015 (Contd..20) 197
Products under Development by Companies, H2 2015 (Contd..21) 198
Products under Development by Companies, H2 2015 (Contd..22) 199
Products under Development by Companies, H2 2015 (Contd..23) 200
Products under Development by Companies, H2 2015 (Contd..24) 201
Products under Development by Companies, H2 2015 (Contd..25) 202
Products under Development by Companies, H2 2015 (Contd..26) 203
Products under Development by Companies, H2 2015 (Contd..27) 204
Products under Development by Companies, H2 2015 (Contd..28) 205
Products under Development by Companies, H2 2015 (Contd..29) 206
Products under Development by Companies, H2 2015 (Contd..30) 207
Products under Development by Companies, H2 2015 (Contd..31) 208
Products under Development by Companies, H2 2015 (Contd..32) 209
Products under Development by Companies, H2 2015 (Contd..33) 210
Products under Development by Companies, H2 2015 (Contd..34) 211
Products under Development by Companies, H2 2015 (Contd..35) 212
Products under Development by Companies, H2 2015 (Contd..36) 213
Products under Development by Companies, H2 2015 (Contd..37) 214
Products under Development by Companies, H2 2015 (Contd..38) 215
Products under Development by Companies, H2 2015 (Contd..39) 216
Products under Development by Companies, H2 2015 (Contd..40) 217
Products under Development by Companies, H2 2015 (Contd..41) 218
Products under Development by Companies, H2 2015 (Contd..42) 219
Products under Development by Companies, H2 2015 (Contd..43) 220
Products under Development by Companies, H2 2015 (Contd..44) 221
Products under Development by Companies, H2 2015 (Contd..45) 222
Products under Development by Companies, H2 2015 (Contd..46) 223
Products under Development by Companies, H2 2015 (Contd..47) 224
Products under Development by Companies, H2 2015 (Contd..48) 225
Products under Development by Companies, H2 2015 (Contd..49) 226
Products under Development by Companies, H2 2015 (Contd..50) 227
Products under Development by Companies, H2 2015 (Contd..51) 228
Products under Development by Companies, H2 2015 (Contd..52) 229
Products under Development by Companies, H2 2015 (Contd..53) 230
Products under Development by Companies, H2 2015 (Contd..54) 231
Products under Development by Companies, H2 2015 (Contd..55) 232
Products under Development by Companies, H2 2015 (Contd..56) 233
Products under Development by Companies, H2 2015 (Contd..57) 234
Products under Investigation by Universities/Institutes, H2 2015 235
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 236
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 237
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 238
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 239
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5) 240
Products under Investigation by Universities/Institutes, H2 2015 (Contd..6) 241
Products under Investigation by Universities/Institutes, H2 2015 (Contd..7) 242
Products under Investigation by Universities/Institutes, H2 2015 (Contd..8) 243
Products under Investigation by Universities/Institutes, H2 2015 (Contd..9) 244
Products under Investigation by Universities/Institutes, H2 2015 (Contd..10) 245
Products under Investigation by Universities/Institutes, H2 2015 (Contd..11) 246
Products under Investigation by Universities/Institutes, H2 2015 (Contd..12) 247
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015 248
Breast Cancer - Pipeline by 4SC AG, H2 2015 249
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H2 2015 250
Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 251
Breast Cancer - Pipeline by AB Science SA, H2 2015 252
Breast Cancer - Pipeline by AbbVie Inc., H2 2015 253
Breast Cancer - Pipeline by AbGenomics International, Inc., H2 2015 254
Breast Cancer - Pipeline by Ability Pharma, SL, H2 2015 255
Breast Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015 256
Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 257
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 258
Breast Cancer - Pipeline by Adaptimmune Limited, H2 2015 259
Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2015 260
Breast Cancer - Pipeline by Aduro BioTech, Inc., H2 2015 261
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015 262
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015 263
Breast Cancer - Pipeline by Advaxis, Inc., H2 2015 264
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 265
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H2 2015 266
Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H2 2015 267
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H2 2015 268
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015 269
Breast Cancer - Pipeline by Affichem SA, H2 2015 270
Breast Cancer - Pipeline by Agilvax, Inc., H2 2015 271
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2015 272
Breast Cancer - Pipeline by Alchemia Limited, H2 2015 273
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015 274
Breast Cancer - Pipeline by Almac Discovery Limited, H2 2015 275
Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2015 276
Breast Cancer - Pipeline by Ambrx, Inc., H2 2015 277
Breast Cancer - Pipeline by Amgen Inc., H2 2015 278
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 279
Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015 280
Breast Cancer - Pipeline by AngioGenex, Inc., H2 2015 281
Breast Cancer - Pipeline by Angion Biomedica Corp., H2 2015 282
Breast Cancer - Pipeline by ANP Technologies, Inc., H2 2015 283
Breast Cancer - Pipeline by AntiCancer, Inc., H2 2015 284
Breast Cancer - Pipeline by Antigen Express, Inc., H2 2015 285
Breast Cancer - Pipeline by Antoxis Limited, H2 2015 286
Breast Cancer - Pipeline by Aphios Corporation, H2 2015 287
Breast Cancer - Pipeline by arGEN-X BV, H2 2015 288
Breast Cancer - Pipeline by Armour Therapeutics Inc., H2 2015 289
Breast Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015 290
Breast Cancer - Pipeline by ArQule, Inc., H2 2015 291
Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 292
Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 293
Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2015 294
Breast Cancer - Pipeline by AskAt Inc., H2 2015 295
Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015 296
Breast Cancer - Pipeline by Astellas Pharma Inc., H2 2015 297
Breast Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 298
Breast Cancer - Pipeline by AstraZeneca Plc, H2 2015 299

List of Figures
Number of Products under Development for Breast Cancer, H2 2015 125
Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015 126
Number of Products under Development by Companies, H2 2015 127
Number of Products under Investigation by Universities/Institutes, H2 2015 165
Comparative Analysis by Late Stage Development, H2 2015 173
Comparative Analysis by Clinical Stage Development, H2 2015 174
Comparative Analysis by Early Stage Products, H2 2015 175
Assessment by Monotherapy Products, H2 2015 661
Assessment by Combination Products, H2 2015 662
Number of Products by Top 10 Targets, H2 2015 663
Number of Products by Stage and Top 10 Targets, H2 2015 663
Number of Products by Top 10 Mechanism of Actions, H2 2015 690
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 690
Number of Products by Top 10 Routes of Administration, H2 2015 721
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 721
Number of Products by Top 10 Molecule Types, H2 2015 723
Number of Products by Stage and Top 10 Molecule Types, H2 2015 723

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *